– USA, CA – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately.
The company is a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
“We are pleased to welcome Ms. Harsch to Satsuma’s Board and look forward to benefitting from her experience and guidance as we advance STS101 through Phase 3 development and toward commercialization,” commented Board Chairman, Dr. Heath Lukatch. “Mutya’s extensive background in the biopharmaceutical industry, and particularly her corporate law and corporate development experience, are highly valuable and complementary to the backgrounds of our other Board members.”
About Mutya Harsch
Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as General Counsel, Chief Legal Officer, and Secretary of VYNE Therapeutics, a publicly-traded biopharmaceutical company.
Prior to joining VYNE Therapeutics in March 2020, Ms. Harsch served as General Counsel and Chief Legal Officer of Foamix Pharmaceuticals Ltd. Ms. Harsch joined Foamix in January 2018, initially serving as its General Counsel and Senior Vice President of Legal Affairs. She has over 20 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions, at Cooley LLP from 2015 to 2017, as a corporate lawyer at Davis Polk & Wardwell from 1999 to 2003 and 2005 to 2015, and as Assistant General Counsel at Warner Chilcott from 2003 to 2005.
Mutya Harsch said, “It is an honor to join Satsuma’s Board at this pivotal juncture in the company’s development. I have high confidence in Satsuma’s strategy and its executive leadership. I look forward to working with the Board and management as Satsuma prepares to potentially file a New Drug Application next year for STS101, which I believe could be an important and exciting therapeutic option for many people who suffer from migraine.”
Ms. Harsch received her JD and BA degrees from the University of California at Berkeley.
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraines. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with a low dose to dose variability. Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina.
For more information: https://www.satsumarx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.